TSX:CSCI - Toronto Stock Exchange - CA22112H1010 - Common Stock - Currency: CAD
TSX:CSCI (7/31/2025, 7:00:00 PM)
5.37
+0.17 (+3.27%)
The current stock price of CSCI.CA is 5.37 CAD. In the past month the price increased by 18.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 314.87M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 268.26M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 236.98M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 200.47M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 124.35M | ||
WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 116.45M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 79.35M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 70.04M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 19.62 | 69.92M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 57.19M | ||
BLU.CA | BLUENERGIES LTD | N/A | 54.52M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M |
COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
COSCIENS BIOPHARMA INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO CA
Employees: 21
Phone: 18439003201
The current stock price of CSCI.CA is 5.37 CAD. The price increased by 3.27% in the last trading session.
The exchange symbol of COSCIENS BIOPHARMA INC is CSCI and it is listed on the Toronto Stock Exchange exchange.
CSCI.CA stock is listed on the Toronto Stock Exchange exchange.
COSCIENS BIOPHARMA INC (CSCI.CA) has a market capitalization of 16.92M CAD. This makes CSCI.CA a Nano Cap stock.
COSCIENS BIOPHARMA INC (CSCI.CA) currently has 21 employees.
COSCIENS BIOPHARMA INC (CSCI.CA) has a support level at 5.19 and a resistance level at 5.81. Check the full technical report for a detailed analysis of CSCI.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CSCI.CA does not pay a dividend.
COSCIENS BIOPHARMA INC (CSCI.CA) will report earnings on 2025-08-11.
COSCIENS BIOPHARMA INC (CSCI.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.02).
ChartMill assigns a technical rating of 7 / 10 to CSCI.CA.
ChartMill assigns a fundamental rating of 3 / 10 to CSCI.CA. CSCI.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months CSCI.CA reported a non-GAAP Earnings per Share(EPS) of -8.02. The EPS increased by 13.07% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -56.4% | ||
ROE | -173.14% | ||
Debt/Equity | 0.19 |
ChartMill assigns a Buy % Consensus number of 83% to CSCI.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.